Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

This study found that the antiandrogen drug enzalutamide reduced TMPRSS2 levels and significantly decreased SARS-CoV-2 entry and infection in lung cells, supporting further clinical trials for COVID-19 treatment.

In this study, Ritlecitinib was reported as a newly approved treatment for alopecia areata that can be used in patients aged 12 and older; after 24 weeks, it resulted in 80% or more scalp hair coverage in treated patients compared to a placebo.

This study concluded that an Emulgel formulation containing Tridax procumbens extract showed promising wound healing and antimicrobial activity, with improved physical properties in the F2 formulation.

This report reviews peer-reviewed case studies indicating potential efficacy of ustekinumab for treating challenging forms of psoriasis but notes the need for further research on cost-effectiveness and risk-benefit.

This study observed that using ex vivo gene therapy to modify skin cells in a pre-graft model improved dermal-epidermal junction adhesion strength and maintained collagen production over time, suggesting a potential treatment approach for recessive dystrophic epidermolysis bullosa skin wounds.

JAK inhibitors, like baricitinib and ritlecitinib, show promise in treating alopecia areata effectively and safely.

This study observed that both ritlecitinib and brepocitinib improved scalp biomarkers in patients with alopecia areata, with associations to hair regrowth seen in this phase 2a trial.

In this case study, a woman with alopecia areata experienced significant hair regrowth after starting ritlecitinib but developed an acneiform eruption, leading to the discontinuation of the drug and subsequent hair loss relapse; the eruption suggests a treatment-limiting adverse effect of JAK inhibitors.

The authors concluded that capecitabine and high-dose toremifene may be an effective treatment option for patients unable to undergo anthracycline or taxane therapies, based on one woman's cancer management.

This study found that vinblastine treatment rapidly increased platelet counts in childhood refractory immune thrombocytopenia, providing effective control of bleeding symptoms, although side effects like neuropathic pain were common and resolved with dose adjustments.

This case report observed hair regrowth following the treatment of alopecia universalis and atopic dermatitis with tofacitinib, a JAK inhibitor.

In this study, data from multiple sources found that Baricitinib significantly promoted hair regrowth and improved patient-reported outcomes in those with severe alopecia, with minimal side effects, over a 36-week period.

This study suggests that the combination of bendamustine and rituximab is at least as effective and possibly offers a better therapeutic index than other standard regimens as first-line treatment for certain lymphoma patients.

The document concludes that an experimental drug may help wound healing in Epidermolysis Bullosa, links Hydroa vacciniforme to EBV, discusses diagnosing hair loss disorders, finds many children with eczema have allergies, reviews the safety of a skin medication in children, notes side effects of a Duchenne's treatment, and identifies a marker for pediatric mastocytosis.

This pharmacovigilance study found that certain systemic medications, including finasteride, bortezomib, and dupilumab, were disproportionately reported in association with eyelid disorders like blepharitis, meibomian gland dysfunction, and chalazia, suggesting these drugs may contribute to these conditions though benefits might still outweigh the risks.

This study found that the oral IRAK4-inhibitors BAY 1834845 and BAY 1830839 reduced skin inflammation and systemic inflammatory responses in healthy volunteers, showing similar pharmacodynamic effects to prednisolone when challenged with topical imiquimod and intravenous LPS.

Baricitinib effectively regrew hair in a woman with alopecia universalis after other treatments failed.

This study found that patients with rheumatoid arthritis, atopic dermatitis, and alopecia areata receiving baricitinib had low incidence rates of adverse events, especially among low-risk individuals, with varying rates among those at higher risk.

In this study, local injection of nanosized recombinant human erythropoietin at the injury site improved skin regeneration and re-epithelialization in a mouse model of deep second-degree burns through coexpression of specific receptors.

In this study, researchers analyzed social media data to assess the comparative safety of arthritis medications, finding increased odds of herpes zoster and perforated bowel with certain therapies. Social media posts expressed more safety concerns than favorable opinions about drug safety.

This article discusses adverse immune-mediated skin reactions associated with TNF-alpha inhibitors, highlighting paradoxical reactions such as psoriasis that occur despite being treated with medications intended to alleviate the condition.

This review highlights promising recent advances in therapies for epidermolysis bullosa, including gene therapy and stem cell approaches, but reports no definitive cures and emphasizes the need for further research.

This abstract provides clinical images of scaly erythematous lesions but does not report any new research findings; further queries should be directed to the corresponding author.

This case report describes the successful treatment of severe bullous erythema multiforme in a patient using cyclosporine, where prior high-dose corticosteroids had only partially worked.

This article reviews the advantages of emulgel as a topical drug delivery system for hydrophobic drugs but provides no new findings.

In this phase 1B study, patients with ER-positive/HER2-negative metastatic breast cancer receiving combined pegylated liposomal doxorubicin and pembrolizumab had a disease control rate of 67% with responses lasting a median of 11 months; the treatment was well tolerated and showed potential for extended use.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.